stockrowOPKO Health, Inc.
OPK Healthcare Diagnostics & Research
- Revenue
- −56.9%
- EPS
- −333.3%
- Free cash flow
- −3.40%
- Total debt
- +40.7%
Quarter to September 2026, against a year earlier
Follow OPK
Alert me
OPKO Health, Inc. (OPK) EV/Sales
As of 5 November 2026, OPKO Health, Inc. (OPK) trades at a EV/Sales of 2.8×. Over the past ten years it has ranged from 0.7× (December 2022) to 84.0× (June 2015); the current reading is higher than 72% of that period. That is below the Diagnostics & Research industry median of 5.2× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.5× | 5.62% |
| FY2024 | 1.4× | (6.63%) |
| FY2023 | 1.5× | 58.80% |
| FY2022 | 1.0× | (46.12%) |
| FY2021 | 1.8× | (5.16%) |
| FY2020 | 1.9× | 68.87% |
| FY2019 | 1.1× | (34.46%) |
| FY2018 | 1.7× | (39.46%) |
| FY2017 | 2.8× | (35.51%) |
| FY2016 | 4.4× | (54.87%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 2.6× | 27.67% |
| Jun 2026 | 2.0× | 34.48% |
| Mar 2026 | 1.5× | (1.49%) |
| Dec 2025 | 1.5× | (20.27%) |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| FRNM Freenome, Inc compare | n/m |
| MYGN Myriad Genetics, Inc. compare | 0.8× |
| FLGT Fulgent Genetics, Inc. compare | 0.8× |
| CSTL Castle Biosciences, Inc. compare | 2.1× |
| VCYT Veracyte, Inc. compare | 2.5× |
| OPK OPKO Health, Inc. | 2.8× |
| NEO NeoGenomics, Inc. compare | 3.3× |
| WGS GeneDx Holdings Corp. compare | 4.2× |
| PSNL Personalis, Inc. compare | 18.6× |
| Diagnostics & Research industry median | 5.2× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)